{"disease":{"id":"glycogen-storage-disease","name":"glycogen storage disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT00231400","title":"Pompe Disease Registry Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT07336394","title":"Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT06813443","title":"Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04454216","title":"GSD VI and GSD IX Natural History","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06396546","title":"'Glycogen Storage Diseases (GSDs) in Indian Children- Establishing an Indian GSD (I-GSD) Registry'","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT02782741","title":"Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT03844022","title":"MRI in McArdle Disease (GSDV)","phase":"","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT02765828","title":"Identification of Tongue Involvement in Late-Onset Pompe Disease","phase":"","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT02318966","title":"Glycosade v UCCS in the Dietary Management of Hepatic GSD","phase":"NA","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Vitaflo International, Ltd","has_results":false},{"nct_id":"NCT03893240","title":"Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Spark Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04399694","title":"Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04909346","title":"Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease","phase":"","overall_status":"TERMINATED","enrollment_count":51,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT05199246","title":"Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Institut de Myologie, France","has_results":false},{"nct_id":"NCT05139316","title":"A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT05017402","title":"Higher Dose of Alglucosidase Alpha for Pompe Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Taipei Veterans General Hospital, Taiwan","has_results":false},{"nct_id":"NCT06735755","title":"A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Beam Therapeutics Inc.","has_results":false},{"nct_id":"NCT05200702","title":"Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Institut de Myologie, France","has_results":false},{"nct_id":"NCT06130228","title":"Nutritional Therapy in Late-onset Pompe Disease","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT01898364","title":"Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT03019406","title":"A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT02801539","title":"Respiratory Muscle Training in L-Onset Pompe Disease (LOPD)","phase":"NA","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT01410890","title":"Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT00567073","title":"Pompe Pregnancy Sub-Registry","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT04311307","title":"Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT05951790","title":"Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Fondazione Don Carlo Gnocchi Onlus","has_results":false},{"nct_id":"NCT02032524","title":"Avalglucosidase Alfa Extension Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT04574830","title":"Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)","phase":"","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT04910776","title":"Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":17,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05164055","title":"Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":17,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT04292938","title":"McArdle Disease Treatment by Ketogenic Diet","phase":"NA","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"IRCCS Eugenio Medea","has_results":false},{"nct_id":"NCT04848779","title":"A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05095727","title":"A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT04708015","title":"Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT05196165","title":"Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III","phase":"","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT06666413","title":"China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":13,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT03970278","title":"Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia","phase":"","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT02919631","title":"Triheptanoin in Mc Ardle","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT00486889","title":"Growth and Development Study of Alglucosidase Alfa","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT04986735","title":"Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin","phase":"","overall_status":"UNKNOWN","enrollment_count":11,"lead_sponsor_name":"Hong Kong Children's Hospital","has_results":false},{"nct_id":"NCT03871673","title":"The Use of Uncooked Sweet Manioc Starch to Treat Hepatic Glycogen Storage Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false},{"nct_id":"NCT03687333","title":"Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT06575829","title":"Treatment Frequency Reduction in Pompe Disease","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT05960617","title":"Efficacy and Safety of Empagliflozin in GSD-Ib Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06843330","title":"Accuracy of Lactate Meter in GSDIa","phase":"","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Connecticut Children's Medical Center","has_results":false},{"nct_id":"NCT04990388","title":"Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT05915910","title":"Prospective Collection of Biospecimen in Pediatric Patients and Adult Guardians Diagnosed With Glycogen Storage Disease Type 1B (GSD1b)","phase":"","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Sanguine Biosciences","has_results":false},{"nct_id":"NCT03011203","title":"Acute Nutritional Ketosis in GSD IIIa","phase":"NA","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT04138251","title":"Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":5,"lead_sponsor_name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}